|
Daehan New Pharm achieved a cumulative operating profit of 14.8 billion won in the third quarter, representing a 44.5% increase compared to the same period last year
2018.11.14
|
|---|
|
Daehan New Pharm announced on the 14th that its cumulative operating profit for the third quarter increased approximately 44.5% year-on-year to 14.8 billion won. Sales declined about 9% to 90.2 billion won, while net profit turned positive.
The significant improvement was driven by expanded sales of high-margin products and the establishment of an efficient management system. The company has been strengthening its product portfolio, improving distribution channels, and optimizing costs, creating a virtuous cycle by reinvesting profits into research and development to drive future growth.
Operating efficiency enhancements contributed to performance improvements, with strategic new products such as ‘Same injection’ ‘Thymosin injection,’ and ‘TESSLIFTSOFT’ at the core of ongoing growth efforts.
‘Same injection,’ approved as a treatment for depression, is also known for its excellent effects in cancer adjunct therapy, liver function improvement, and pain management, and is expected to continue the reputation of ‘Luthione Injection’ (commonly known as ‘Baekok Injection’) as a sales leader.
The company has an exclusive sales agreement for the premium mesh-structured dissolvable thread ‘TESSLIFTSOFT’ and is actively marketing its differentiated product strengths.
Through diversification of sales and improvement of profitability structure, sales increased from 56.7 billion won in 2013 to 130.8 billion won last year, while operating profit rose from 6 billion won to 13.1 billion won. |


Home